Pacific Biosciences of California, Inc. entered a sales agreement with Allen & Company LLC for an at-the-market offering of common stock with aggregate sales proceeds of up to $100,000,000. Allen will receive compensation of up to 3.0% of gross proceeds.
PACB · Pacific Biosciences Of California, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
PacBio reported third-quarter 2026 revenue growth of 6% and a 15% gross profit decline. Cash, cash equivalents and investments were $199.4 million at September 30, 2026, down 29% from December 31, 2025.
PACBIO reported third quarter 2026 revenue of $40.6 million, up 6% year over year, and narrowed 2026 revenue guidance to $155 to $160 million; non-GAAP gross margin fell to 36% from 42%.
Pacific Biosciences of California, Inc. reported $40.6 million in third-quarter revenue for the quarter ended September 30, 2026. Jim Gibson stepped down as CFO, Mark Van Oene became interim CFO, and 2026 revenue guidance is $155 million to $160 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 4, 2026TL;DR. Q3 revenue grew 6% year over year as SPRQ-Nx adoption expanded, clinical consumables grew more than 20%, and new clinical and AI collaborations broadened PacBio’s opportunity. The outlook includes lower operating expenses and 2028 cash-flow break-even, but consumables pull-through and gross margin declined, funding constraints persisted, cash fell, and PacBio continued to report a substantial net loss.
- + Q3 revenue grew 6% year over year to $40.6 million, with instrument revenue increasing 16% to $13.2 million.
- + SPRQ-Nx adoption reached over half of Revio consumables revenue, with two-thirds of the installed base upgrading by quarter-end.
- + Clinical consumables revenue was growing more than 20% year over year and represented more than 20% of overall business.
- + The GeneDx partnership is expected to deepen PacBio's role in rare disease and support its clinical growth strategy.
- + The multi-year Verily Health collaboration is expected to bring HiFi long-read data to a research community of more than 20,000 users.
- + Restructuring savings are expected to reduce 2026 operating expenses to $203–$207 million, with cash-flow break-even expected in 2028.
- − Consumables revenue declined year over year to $20.8 million from $21.3 million as sequencing activity grew faster than purchases.
- − Annualized Revio pull-through was ~$204,000 versus ~$236,000 in the prior-year quarter.
- − Non-GAAP gross margin declined to 36% from 42% because of higher memory costs and Vega manufacturing-transition costs.
- − Americas instrument revenue declined approximately 24% as academic and government funding uncertainty constrained capital purchasing.
- − Cash, cash equivalents, and investments declined to approximately $199.4 million from $279.5 million at December 31, 2025.
- − PacBio reported a $32.8 million non-GAAP net loss, or 11 cents per share.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Annualized Revio pull-through per system | $202,000 | Q2 2026 | — |
| Revio system placements | 20 | Q2 2026 | — |
| Vega system placements | 26 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PACB
this stock
Pacific Biosciences Of California, Inc.
|
$613.34M | +4.8% | +3.0% | — | 17.2% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 22
Pacific Biosciences of California, Inc. entered a sales agreement with Allen & Company LLC for an at-the-market offering of common stock with aggregate sales proceeds of up to $100,000,000. Allen will receive compensation of up to 3.0% of gross proceeds.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PACB | -13.1% | +13.3% | +55.6% | -24.8% | +4.8% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -15.7% | +14.5% | +55.1% | -24.6% | -5.8% |